On October 21, Argenx SE rose 5.75% in Regular Trading, trading at $873.085, with turnover of $250 million.
The move followed a fresh brokerage note saying the stock's recent volatility has been driven by drug-development updates and that investors may be undervaluing the company's breakthrough in celiac disease, while maintaining an outperform view.
Recent background has been mixed: positive phase 3 data in August showed Vyvgart Hytrulo met its primary endpoint in autoimmune myositis, helping lift sentiment, while an October decision to discontinue the phase 3 Sjogren's disease trial after a futility review pressured shares. At the same time, the company said its phase 2 FB102 study in celiac disease met the primary endpoint, with statistically significant and clinically relevant efficacy and no new safety signals, which appears to be supporting sentiment recovery.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments